We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Light Switches Neurons On and Off

By Biotechdaily staff writers
Posted on 23 Apr 2007
Researchers have invented a genetically-engineered way to turn the electrical impulses of brain cells on and off with pulses of blue and yellow light--in synch with the split-second pace of real time neuronal activity.

The novel technique borrows genes from light-responsive algae and bacteria to unravel the intricate workings of brain circuits with extreme precision. More...
Initial tests in intact mouse circuits and tiny living worms promise new hope for understanding--and eventually treating-- psychiatric and neurologic disorders.

In the future, brain disorders could potentially be managed with light-emitting implants, envisions U.S. National Institute of Mental Health (NIMH; Bethesda, MD, USA) grantee Dr. Karl Deisseroth, Stanford University (Palo Alto, CA, USA), whose research team reported their findings in the April 5, 2007, issue of the journal Nature.

The wide variety of neuronal cell types involved in mental illness aren't conveniently clumped together, but rather sparsely embedded in complex circuitry, explained Dr. Deisseroth, an engineer as well as a psychiatrist who treats depressed patients.

Much brain circuit activity happens so quickly and at such a micro, neuron-specific level that it eludes detection even with the most advanced imaging technologies. Neuroscientists need more precise and reversible methods for activating and inactivating neurons in experimental models.

To address these issues, Dr. Deisseroth's team, which included German collaborators, created probes that selectively target particular types of neurons. They loaded a deactivated virus with genes from light-sensitive primitive organisms and fluorescent proteins or other markers. The loaded virus then carried the genes into specific neurons, where the genes began producing proteins necessary for turning the neurons on and off--just as they do in the primitive organisms.

To turn neurons on, they borrowed a gene (ChR2) from green algae that opens the flow of sodium into its single cell in response to blue light to control its movement towards light in order to conduct photosynthesis. To turn neurons off, they adapted a gene (NpHR) from a primitive bacterium native to salt lakes in Egypt. In response to yellow light, it regulates salt balance by pumping chloride into its cell.

In one experiment in the study, cultured rat neurons that had been loaded with the ChR2 and NpHR genes fired in lockstep with pulses of blue light, but stopped firing in the presence of yellow light. The researchers have also demonstrated the same on/off control in living mouse circuitry and in tiny translucent worms, whose swimming behavior was stopped and started by targeting a specific class of motor neurons.

The scientists suggest that the new tools could be used with existing imaging approaches in living animals engaged in behaviors to pinpoint how neural activity patterns relate to brain-circuit functioning. Dr. Deisseroth said the tools might also find application in determining the therapeutic potential of experimental drugs. He envisions the possibility, in the more distant future, of genetic targeting of neurons involved in disease processes. For example, light stimulation could potentially offer a more precise and less invasive alternative to electrical stimulation for treating disorders like Parkinson's disease and depression.

This accomplishment is a key step toward the important goal of mapping neural circuit dynamics on a millisecond timescale. This approach could provide new insights into the complex dynamics of brain function in a range of diseases, said National Institutes of Health Director Elias A. Zerhouni, M.D. The work is also a prime example of the highly innovative approaches to major challenges in biomedical research that we support through the [US National Institutes of Health] NIH Director's Pioneer Award program.

Dr. Deisseroth is a recipient of a Pioneer Award. NIH provides a dozen or so such grants each year to scientists of exceptional creativity for approaches that have the potential to produce an unusually high impact. His work was also funded, in part, by the National Institute on Drug Abuse.


Related Links:
National Institute of Mental Health
Stanford University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.